Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric species

Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric species

Abstract Background The aggregation of the protein ɑ-synuclein (ɑS) underlies a range of increasingly common neurodegenerative disorders including Parkinson’s disease. One widely explored therapeutic strategy for these conditions is the use of antibodies to target aggregated ɑS, although a detailed...

Full description

Bibliographic Details
Main Authors: Marija Iljina, Liu Hong, Mathew H. Horrocks, Marthe H. Ludtmann, Minee L. Choi, Craig D. Hughes, Francesco S. Ruggeri, Tim Guilliams, Alexander K. Buell, Ji-Eun Lee, Sonia Gandhi, Steven F. Lee, Clare E. Bryant, Michele Vendruscolo, Tuomas P. J. Knowles, Christopher M. Dobson, Erwin De Genst, David Klenerman
Format: Article
Language:English
Published: BMC 2017-07-01
Series:BMC Biology
Subjects:
Protein aggregation
Amyloid toxicity
Neurodegeneration
Aggregation inhibitors
Antibody
Single-molecule fluorescence
Online Access:http://link.springer.com/article/10.1186/s12915-017-0390-6

Internet

http://link.springer.com/article/10.1186/s12915-017-0390-6

Similar Items